AVID BIOSERVICES INC (CDMO)
US05368M1062 - Common Stock
Taking everything into account, CDMO scores 3 out of 10 in our fundamental rating. CDMO was compared to 588 industry peers in the Biotechnology industry. CDMO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CDMO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CDMO had negative earnings in the past year.
In the past year CDMO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CDMO reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CDMO reported negative operating cash flow in multiple years.
1.2 Ratios
CDMO has a Return On Assets of -2.52%. This is amongst the best in the industry. CDMO outperforms 92.83% of its industry peers.
Looking at the Return On Equity, with a value of -6.23%, CDMO belongs to the top of the industry, outperforming 92.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.52% | ||
| ROE | -6.23% | ||
| ROIC | N/A |
ROA(3y)10.36%
ROA(5y)1.12%
ROE(3y)25.91%
ROE(5y)4.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDMO's Gross Margin of 12.53% is fine compared to the rest of the industry. CDMO outperforms 74.91% of its industry peers.
CDMO's Gross Margin has improved in the last couple of years.
CDMO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y47.82%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDMO has more shares outstanding
Compared to 5 years ago, CDMO has more shares outstanding
CDMO has a better debt/assets ratio than last year.
2.2 Solvency
CDMO has an Altman-Z score of 0.02. This is a bad value and indicates that CDMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CDMO (0.02) is better than 60.75% of its industry peers.
A Debt/Equity ratio of 0.81 indicates that CDMO is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.81, CDMO is doing worse than 76.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.02 |
ROIC/WACCN/A
WACC7.31%
2.3 Liquidity
CDMO has a Current Ratio of 1.35. This is a normal value and indicates that CDMO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.35, CDMO is doing worse than 85.32% of the companies in the same industry.
CDMO has a Quick Ratio of 1.35. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
CDMO has a Quick ratio of 0.85. This is amonst the worse of the industry: CDMO underperforms 89.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.85 |
3. Growth
3.1 Past
CDMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -440.00%.
The Revenue has been growing slightly by 5.03% in the past year.
The Revenue has been growing by 22.74% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-440%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-650%
Revenue 1Y (TTM)5.03%
Revenue growth 3Y35.74%
Revenue growth 5Y22.74%
Revenue growth Q2Q-26.94%
3.2 Future
The Earnings Per Share is expected to grow by 163.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 28.94% on average over the next years. This is a very strong growth
EPS Next Y-2828.5%
EPS Next 2Y-189.4%
EPS Next 3Y163.81%
EPS Next 5YN/A
Revenue Next Year-6.55%
Revenue Next 2Y5.63%
Revenue Next 3Y12.83%
Revenue Next 5Y28.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CDMO. In the last year negative earnings were reported.
Also next year CDMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDMO's earnings are expected to grow with 163.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-189.4%
EPS Next 3Y163.81%
5. Dividend
5.1 Amount
CDMO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVID BIOSERVICES INC
NASDAQ:CDMO (5/1/2024, 3:51:24 PM)
After market: 7.67 0 (0%)7.67
+0.04 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap485.05M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.52% | ||
| ROE | -6.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-440%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2828.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.03%
Revenue growth 3Y35.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y